FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282425> ?p ?o ?g. }

• W4379282425 endingPage "3570" @default.
• W4379282425 startingPage "3570" @default.
• W4379282425 abstract "3570 Background: Microsatellite instability (MSI) is currently the only predictive biomarker of efficacy of immune checkpoint inhibitors (ICI) in metastatic colorectal cancers (mCRC). However, 10-40% of patients with MSI mCRC will experience a primary resistance to ICI. Methods: In a cohort of 103 patients with MSI mCRC treated with ICI, 3’RNAseq was performed from primary tumors resected before the beginning of ICI. Previously described single-cell transcriptomic signatures of tumor microenvironment (TME) were analysed. Results: The unsupervised clustering of this cohort allowed the identification of three clusters of tumors with distinct transcriptional profiles: cluster A (“stromal HIGH -proliferation LOW ”), cluster B (“stromal HIGH -proliferation MED ”), and cluster C (“stromal LOW -proliferation HIGH ”), with an enrichment of patients progressing at first disease assessment under ICI in the cluster A (30% vs 12% in cluster B and 8.1% in cluster C, p = 0.074). Progression-free survival (PFS) was also significantly shorter in patients belonging to cluster A, compared to clusters B or C (p < 0.001) with 2-year PFS rates of 33.5%, 80.5% and 78.3%, respectively. Similar results were observed for overall survival (OS).In multivariate analysis, PFS was still significantly longer in patients belonging to cluster B (HR: 0.26 95%CI 0.11-0.58, p = 0.001) and cluster C (HR: 0.35 95%CI 0.16-0.78, p = 0.01), compared to patients belonging to cluster A (Table). No association of identified clusters with PFS during non-ICI-based regimens was identified. Conclusions: This unsupervised transcriptomic classification identified three groups of MSI mCRCs with different compositions of TME cells and proliferative capacities of TME/tumor cells. The “stromal HIGH -proliferation LOW ” cluster is associated with a lower efficacy of ICI. [Table: see text]" @default.
• W4379282425 created "2023-06-05" @default.
• W4379282425 creator A5004426494 @default.
• W4379282425 creator A5005516545 @default.
• W4379282425 creator A5013247333 @default.
• W4379282425 creator A5013388524 @default.
• W4379282425 creator A5028325185 @default.
• W4379282425 creator A5031596792 @default.
• W4379282425 creator A5042627121 @default.
• W4379282425 creator A5043936629 @default.
• W4379282425 creator A5049363884 @default.
• W4379282425 creator A5051613962 @default.
• W4379282425 creator A5052188741 @default.
• W4379282425 creator A5056273091 @default.
• W4379282425 creator A5060891866 @default.
• W4379282425 creator A5066899111 @default.
• W4379282425 creator A5079437223 @default.
• W4379282425 creator A5081985776 @default.
• W4379282425 creator A5083651413 @default.
• W4379282425 creator A5089818289 @default.
• W4379282425 date "2023-06-01" @default.
• W4379282425 modified "2023-10-18" @default.
• W4379282425 title "Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors." @default.
• W4379282425 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.3570" @default.
• W4379282425 hasPublicationYear "2023" @default.
• W4379282425 type Work @default.
• W4379282425 citedByCount "0" @default.
• W4379282425 crossrefType "journal-article" @default.
• W4379282425 hasAuthorship W4379282425A5004426494 @default.
• W4379282425 hasAuthorship W4379282425A5005516545 @default.
• W4379282425 hasAuthorship W4379282425A5013247333 @default.
• W4379282425 hasAuthorship W4379282425A5013388524 @default.
• W4379282425 hasAuthorship W4379282425A5028325185 @default.
• W4379282425 hasAuthorship W4379282425A5031596792 @default.
• W4379282425 hasAuthorship W4379282425A5042627121 @default.
• W4379282425 hasAuthorship W4379282425A5043936629 @default.
• W4379282425 hasAuthorship W4379282425A5049363884 @default.
• W4379282425 hasAuthorship W4379282425A5051613962 @default.
• W4379282425 hasAuthorship W4379282425A5052188741 @default.
• W4379282425 hasAuthorship W4379282425A5056273091 @default.
• W4379282425 hasAuthorship W4379282425A5060891866 @default.
• W4379282425 hasAuthorship W4379282425A5066899111 @default.
• W4379282425 hasAuthorship W4379282425A5079437223 @default.
• W4379282425 hasAuthorship W4379282425A5081985776 @default.
• W4379282425 hasAuthorship W4379282425A5083651413 @default.
• W4379282425 hasAuthorship W4379282425A5089818289 @default.
• W4379282425 hasConcept C104317684 @default.
• W4379282425 hasConcept C121608353 @default.
• W4379282425 hasConcept C126322002 @default.
• W4379282425 hasConcept C143998085 @default.
• W4379282425 hasConcept C150194340 @default.
• W4379282425 hasConcept C162317418 @default.
• W4379282425 hasConcept C164866538 @default.
• W4379282425 hasConcept C16930146 @default.
• W4379282425 hasConcept C180754005 @default.
• W4379282425 hasConcept C199360897 @default.
• W4379282425 hasConcept C2777701055 @default.
• W4379282425 hasConcept C2779767149 @default.
• W4379282425 hasConcept C2780851360 @default.
• W4379282425 hasConcept C2781197716 @default.
• W4379282425 hasConcept C41008148 @default.
• W4379282425 hasConcept C502942594 @default.
• W4379282425 hasConcept C526805850 @default.
• W4379282425 hasConcept C54355233 @default.
• W4379282425 hasConcept C61320498 @default.
• W4379282425 hasConcept C71924100 @default.
• W4379282425 hasConcept C72563966 @default.
• W4379282425 hasConcept C86803240 @default.
• W4379282425 hasConceptScore W4379282425C104317684 @default.
• W4379282425 hasConceptScore W4379282425C121608353 @default.
• W4379282425 hasConceptScore W4379282425C126322002 @default.
• W4379282425 hasConceptScore W4379282425C143998085 @default.
• W4379282425 hasConceptScore W4379282425C150194340 @default.
• W4379282425 hasConceptScore W4379282425C162317418 @default.
• W4379282425 hasConceptScore W4379282425C164866538 @default.
• W4379282425 hasConceptScore W4379282425C16930146 @default.
• W4379282425 hasConceptScore W4379282425C180754005 @default.
• W4379282425 hasConceptScore W4379282425C199360897 @default.
• W4379282425 hasConceptScore W4379282425C2777701055 @default.
• W4379282425 hasConceptScore W4379282425C2779767149 @default.
• W4379282425 hasConceptScore W4379282425C2780851360 @default.
• W4379282425 hasConceptScore W4379282425C2781197716 @default.
• W4379282425 hasConceptScore W4379282425C41008148 @default.
• W4379282425 hasConceptScore W4379282425C502942594 @default.
• W4379282425 hasConceptScore W4379282425C526805850 @default.
• W4379282425 hasConceptScore W4379282425C54355233 @default.
• W4379282425 hasConceptScore W4379282425C61320498 @default.
• W4379282425 hasConceptScore W4379282425C71924100 @default.
• W4379282425 hasConceptScore W4379282425C72563966 @default.
• W4379282425 hasConceptScore W4379282425C86803240 @default.
• W4379282425 hasIssue "16_suppl" @default.
• W4379282425 hasLocation W43792824251 @default.
• W4379282425 hasOpenAccess W4379282425 @default.
• W4379282425 hasPrimaryLocation W43792824251 @default.
• W4379282425 hasRelatedWork W2000210255 @default.
• W4379282425 hasRelatedWork W2514547815 @default.
• W4379282425 hasRelatedWork W2911032670 @default.
• W4379282425 hasRelatedWork W2992955766 @default.

• next